Deal Structure Trade Space
Most BD conversations anchor on licensing because that’s the default. But the same asset could be 20–60% more valuable under a different structure — or significantly less. Below are four representative assets run through all five deal structures, ranked by total value to the licensor.
Computed by optimizeDealStructure() (backtest-validated engine). Upfront, milestone allocation, and royalty structures vary by deal type per the DEAL_TYPE_CAPTURE and PHASE_ALLOCATION tables. All figures in $M unless noted otherwise.
Phase 2 oncology mAb
NSCLC, $2B peak, small-biotech licensor
Your asset would be worth 422% more as a Acquisition (M&A) ($652M) than as Licensing ($125M). Based on phase2 oncology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.
Acquisition
#1Cash now for full ownership. Highest upfront ratio.
Top-ranked: Acquisition (M&A) delivers $652M total deal value with $652M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.
Co-development
#2Shared R&D cost, shared upside. Lower upfront, higher retained NPV.
Co-development: $316M total (22% upfront) — 153% better than your selection.
Collaboration
#3Research funding + joint milestones. Early-stage partnership.
Research Collaboration: $182M total (20% upfront) — 46% better than your selection.
Licensing
#4Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $125M total — comparable to your selection (within 20%).
Option
#5Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $140M total — comparable to your selection (within 20%).
Phase 3 rare disease gene therapy
DMD, $1B peak, orphan designation
Your asset would be worth 247% more as a Acquisition (M&A) ($2.2B) than as Licensing ($638M). Based on phase3 rareDisease benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.
Acquisition
#1Cash now for full ownership. Highest upfront ratio.
Top-ranked: Acquisition (M&A) delivers $2.2B total deal value with $2.2B upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.
Co-development
#2Shared R&D cost, shared upside. Lower upfront, higher retained NPV.
Co-development: $821M total (26% upfront) — 29% better than your selection.
Licensing
#3Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $638M total — comparable to your selection (within 20%).
Collaboration
#4Research funding + joint milestones. Early-stage partnership.
Research Collaboration: $759M total — comparable to your selection (within 20%).
Option
#5Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $440M total — 31% lower than your selection.
Phase 2 immunology bispecific
Atopic dermatitis, $1.5B peak, mid-biotech licensor
Your asset would be worth 283% more as a Acquisition (M&A) ($414M) than as Licensing ($108M). Based on phase2 immunology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.
Acquisition
#1Cash now for full ownership. Highest upfront ratio.
Top-ranked: Acquisition (M&A) delivers $414M total deal value with $414M upfront (100% upfront ratio). Best fit for the licensor's risk and cash preferences.
Co-development
#2Shared R&D cost, shared upside. Lower upfront, higher retained NPV.
Co-development: $228M total (22% upfront) — 111% better than your selection.
Collaboration
#3Research funding + joint milestones. Early-stage partnership.
Research Collaboration: $133M total (20% upfront) — 23% better than your selection.
Licensing
#4Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $108M total — comparable to your selection (within 20%).
Option
#5Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $125M total — comparable to your selection (within 20%).
Phase 1 platform RNAi
Cardiovascular, $800M peak, early-stage option play
Co-development
#1Shared R&D cost, shared upside. Lower upfront, higher retained NPV.
Top-ranked: Co-development delivers $156M total deal value with $16M upfront (10% upfront ratio). Best fit for the licensor's risk and cash preferences.
Option
#2Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $107M total — comparable to your selection (within 20%).
Collaboration
#3Research funding + joint milestones. Early-stage partnership.
Research Collaboration: $70M total — comparable to your selection (within 20%).
Licensing
#4Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $-80M total — comparable to your selection (within 20%).
Acquisition
#5Cash now for full ownership. Highest upfront ratio.
Acquisition (M&A): $-164M total — comparable to your selection (within 20%).
How we compute this
For each asset, the engine runs calculateRNPV() five times — one per deal type. Peak sales, PoS, discount rate, and cash flow timing are constant across runs; only deal-type-specific upfront / milestone / royalty structure varies. The resulting implied deal values are the headline numbers shown in each card.
Rankings apply a licensor preference profile: clinical-stage biotechs with short cash runway weight cash-now higher, large pharma weights retained upside higher. The profile shifts ties but doesn’t override a meaningfully better headline value.
We surface a recommendation only when the top alternative beats the user’s current structure by ≥20%. Below that threshold, the signal is too weak to override the strategic context (tax, IP, control, relationship dynamics) that drive the choice in practice. This tool informs the conversation; it doesn’t replace it.